ADMA stockholder suit alleges channel-stuffing and a hidden distributor deal

A stockholder is suing ADMA Biologics' leaders, alleging they inflated the drugmaker's revenue - months after a short-seller called its growth “a fiction.” 

The lawsuit, filed September 2 in federal court in New Jersey, is a derivative action - a case a shareholder brings on the company's behalf to recover money for the company itself. The defendants are ADMA's chief executive, its vice chairman, its former finance chief and five board directors. For anyone who follows small-cap biopharma, it is a sharp look at how fast a growth story can wobble once the numbers get pressure-tested. 

Start with the product. ADMA's top seller is ASCENIV, an immune-deficiency treatment that the complaint says brought in $362.5 million of the company's $510.2 million in fiscal 2025 revenue. Beginning in mid-2025, the filing alleges, ADMA leaned on its distributors to take on far more ASCENIV than they could sell - offering rebates and payment terms as long as 120 days - and booked the shipments as revenue even though, according to the complaint, there was no real demand behind them. The filing calls this a “channel-stuffing scheme.” 

The alleged giveaway sits in the company's own numbers. The complaint says ADMA's days sales outstanding - roughly, how long it takes to get paid after a sale - jumped from 43 days to 113 days in a single year. It alleges one of ADMA's two biggest distributors was sitting on four to six months of inventory, up from about a month under normal conditions. Two distributors, the filing says, made up about 73% of ADMA's revenue. 

The second thread is a company called Genesis Bio. The complaint alleges ADMA distributed ASCENIV through Genesis Bio - which it says operates out of ADMA's own headquarters and is controlled by ADMA's vice chairman, a co-founder and the father of the chief executive - without ever disclosing the arrangement as a related-party deal in any SEC filing. 

Then the stock cracked. On March 24, the complaint says, short-seller Culper Research published a report calling ADMA's growth “a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor,” and estimating that “absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported.” The filing says the shares fell more than 16% that day, another 15% after ADMA responded, and 13.9% more on an analyst downgrade - about a 45% slide over three trading days. 

What gives the case its bite is the timing of the trades. The complaint alleges six of the defendants sold 1,612,694 shares for $30,066,612 while the stock was, in its telling, propped up - including the chief executive, who it says sold 927,212 shares for about $16.4 million, most of it outside a preset trading plan. Around the same stretch, the filing says, the board had ADMA buy back 8,673,226 of its own shares for about $142.3 million, including a $125 million accelerated repurchase arranged with JPMorgan three weeks before the Culper report. The complaint adds that JPMorgan was the same lender to which the chief executive had pledged $12.8 million of his ADMA stock as collateral for a personal credit line. 

The suit brings claims including securities-law violations, breach of fiduciary duty and unjust enrichment - a legal term for keeping a benefit you weren't entitled to. It notes a related securities class action was filed in the same court in June against ADMA and three of the individuals. 

For the advisors, analysts and compliance teams who screen names like this, the case reads as a checklist of warning signs. Every red flag the complaint points to was hiding in ADMA's own public filings: a collection metric drifting the wrong way inside a 10-K, a related-party relationship that never made it into a disclosure, and insider sales that broke sharply from years of holding - several defendants, the filing says, had not sold a share on the open market in years before the alleged conduct began. None of it required inside information to spot. It required reading the footnotes. 

The allegations are untested, and no court has ruled.